- B2B
- Public StagePublicly traded company
- Top InvestorsThis company has received a significant amount of investment from top investors
Roivant Sciences careers
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.
The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs.
In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs.
In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
Senior Solution Architect, Finance Systems
In office • New York City
$140k – $177k2 weeks ago
Rotational Analyst
In office • New York City
1 month ago
Senior Analyst, Roivant Health
In office • New York City
$115k – $150k2 months ago
Founding Engineer, Roivant Health
In office • New York City
$130k – $180kEmily Formea
Molly Horgan
Worked at @Apple, @LaunchSquad
Molly Horgan
Talent Acquisition Coordinator at Roivant Sciences
Total raised
$1.9B
Funded over
4 rounds
Latest round
